Valdecoxib’in kolon kanser hücreleri (ht 29 ve sw 620) üzerine olan etkilerinin ATR-FTIR spektroskopisi ile moleküler karakterizasyonu.


Tezin Türü: Yüksek Lisans

Tezin Yürütüldüğü Kurum: Orta Doğu Teknik Üniversitesi, Türkiye

Tezin Onay Tarihi: 2014

Tezin Dili: İngilizce

Öğrenci: Aysun İnan Genç

Eş Danışman: FERİDE SEVERCAN, SREEPARNA BANERJEE

Özet:

Colorectal cancer is the third most common malignancy and the fourth most frequent cause of cancer deaths worldwide, with 945,000 estimated new cases and 492,000 deaths per year in industrialized countries. Chronic inflammation of the bowel is associated with increased levels of pro-inflammatory cytokines and the increased signaling, which plays important roles in the development of carcinoma. During chronic inflammation COX-2 levels are dramatically increased which is the main enzyme in the arachidonic acid pathway. It is observed from the previous studies that COX-2 inhibitors have chemopreventive as well as therapeutic effects on different cancer types. Therefore, the effect of COX-2 inhibitors on cancer therapy is an area of high interest. In this study Valdecoxib (VLX) is chosen as a member of COX-2 inhibitors. There are lots of studies related to the effect of COX-2 inhibitors on colon cancer at molecular level, but there is a limited number of studies at structural level. In this study, it was aimed to investigate the alterations in the macromolecules of HT 29 and SW 620 colon cancer cell lines after VLX treatment using ATR-FTIR spectroscopic techniques. Spectral analysis at C-H region (3030-2800 cm-1) revealed that lipid concentration, order and membrane fluidity of two colon cancer cell lines were highly affected due to VLX treatment. Furthermore, spectral analysis at fingerprint region (1800-900 cm-1) showed that protein concentration parameters were also affected due to VLX treatment. In addition, in this study it was also observed that the above results were COX-2 independent. After additional research, VLX may have a chance as an adjuvant therapy in the treatment of colon cancer.